Shanghai Medicilon Inc Cash Flow Conversion Efficiency
Shanghai Medicilon Inc cash flow conversion efficiency. Based on the latest financial reports, Shanghai Medicilon Inc (688202) has a cash flow conversion efficiency ratio of -0.010x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-17.10 Million ≈ $-2.50 Million USD) by net assets (CN¥1.74 Billion ≈ $254.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shanghai Medicilon Inc (2016–2025)
Cash flow conversion efficiency of Shanghai Medicilon Inc from 2016 to 2025. This chart illustrates how Shanghai Medicilon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Shanghai Medicilon Inc (688202) stock price for real-time trading data and today's change.
Shanghai Medicilon Inc Cash Flow Conversion Ratio Explained
Shanghai Medicilon Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shanghai Medicilon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Medicilon Inc ranked by their cash flow conversion efficiency. Also see market cap of Shanghai Medicilon Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
-0.042x |
|
Bilia AB (publ)
ST:BILI-A
|
0.122x |
|
Tibet Mineral Development Co Ltd
SHE:000762
|
0.009x |
|
Suning Commerce Group Co Ltd
SHE:002024
|
0.015x |
|
YFY Inc
TW:1907
|
0.018x |
|
Scatec Solar OL
OL:SCATC
|
0.013x |
|
Youngone Holdi
KO:009970
|
0.067x |
|
Shanghai Electric Wind Power Group Co. Ltd. A
SHG:688660
|
-0.212x |
Annual Cash Flow Conversion Efficiency for Shanghai Medicilon Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Medicilon Inc from 2016 to 2025. Review Shanghai Medicilon Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.93 Billion ≈ $283.04 Million |
CN¥105.17 Million ≈ $15.39 Million |
0.054x | +611.58% |
| 2024-12-31 | CN¥2.14 Billion ≈ $313.17 Million |
CN¥-22.75 Million ≈ $-3.33 Million |
-0.011x | -180.10% |
| 2023-12-31 | CN¥2.51 Billion ≈ $367.41 Million |
CN¥33.32 Million ≈ $4.88 Million |
0.013x | +199.71% |
| 2022-12-31 | CN¥1.60 Billion ≈ $234.54 Million |
CN¥-21.33 Million ≈ $-3.12 Million |
-0.013x | -103.90% |
| 2021-12-31 | CN¥1.33 Billion ≈ $194.26 Million |
CN¥452.94 Million ≈ $66.28 Million |
0.341x | +86.49% |
| 2020-12-31 | CN¥1.14 Billion ≈ $166.18 Million |
CN¥207.77 Million ≈ $30.40 Million |
0.183x | +214.00% |
| 2019-12-31 | CN¥1.00 Billion ≈ $146.42 Million |
CN¥58.30 Million ≈ $8.53 Million |
0.058x | -71.49% |
| 2018-12-31 | CN¥347.89 Million ≈ $50.91 Million |
CN¥71.11 Million ≈ $10.41 Million |
0.204x | -21.38% |
| 2017-12-31 | CN¥287.32 Million ≈ $42.04 Million |
CN¥74.70 Million ≈ $10.93 Million |
0.260x | +87.44% |
| 2016-12-31 | CN¥246.09 Million ≈ $36.01 Million |
CN¥34.13 Million ≈ $4.99 Million |
0.139x | -- |
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow ch… Read more